Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas | MicrobiomeTrials← Back to trialsNCT06156410
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-10-24Est. Completion: 2027-11
Enrollment target: 30 participants Locations- University of California San Francisco, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
Other microbiome trials you might be interested in
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029
Ewing SarcomaColorectal Adenocarcinoma
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant huma…
Scottsdale, United StatesEst. completion Dec 2028